Hypothesizing that PARP-inhibition could induce synergistic cytotoxicity in CHFR expressing lung cancer cell lines, we performed cytotoxicity assays in seven lung cancer cell lines (A549, EKVX, H596, H522, Hop-62, H460 and H2023) using docetaxel and the PARP-inhibitor ABT-888 either alone or in combination. The gene discussed is PARP1; the disease is lung carcinoma.